Sysmex Connect – October 2021
Sixty Seconds on Haemostasis Dr. Chris Gardiner (Senior Research fellow at the formerly Haemostasis Research Unit (HRU) at UCLH, London, UK) along with colleagues at HRU-UCLH, performed a performance evaluation of chemiluminescence enzyme immunoassays (CLEIA) on the new Sysmex CN-6500 haemostasis analyser. In July this year, Dr, Gardiner presented his findings for testing Haemostatic and Fibrinolytic Activation Markers and their potential Clinical Utility in COVID-19 Patients on the CN-6500 system. Krishna Ram - Hi Dr. Gardiner, firstly thank you for taking the time for this 60 second interview. How are you? You’re back in the lab, working in Leeds…
Dr. Gardiner - In time, I can see these assays providing useful information in patients with severe COVID-19, sepsis and atypical DIC, to facilitate personalised medicine for these patients. These assays also have potential applications in cancer medicine. The benefit with the CN-6500 is the ability to automatically perform classical haemostasis assays alongside these CLEIA assays; TM, TAT, tPAI-C and PIC from a single citrate sample tube.
Dr. Gardiner - It’s been a busy few months, I moved from Buckinghamshire to West Yorkshire in June. I’m still settling in, but I’ve taken every opportunity to explore the Yorkshire Dales. Yes, I started work in the specialist coagulation lab at St James’ University Hospital in July.
Krishna Ram - What makes the CN-6500 analyser stand-out against other automated CLEIA systems and traditional immunoassays?
Krishna Ram - Have you missed lab-life and do you miss working with Sysmex analysers in Haemostasis?
Dr. Gardiner - The wide analy tical measurement ranges, reproducibility for all the assays, along with the ease of use of the software and sample processing speed of the CN-6500. The time taken to analyse PT, APTT, Fib and D-dimer while simultaneously performing the four CLEIA tests on the same sample was 23 minutes and 30 seconds. This is a saving of many hours based on ELISA methodology for these four CLEIA assays. The integration of chemiluminescence detection on to a main line haemostasis analyser has achieved excellent comparability of the CN-6500 against the predicate HISCL-5000 system, a fully automated rapid immunochemistry analyser. Comparability of TM, TAT, PIC and tPAI-C in 230 clinical plasma samples between the CN-6500 and HISCL-5000 analysers.
Dr. Gardiner - It’s good to be back in a clinical lab at the sharp end of things. It’s the first time I have worked in a haemophilia comprehensive care centre. I’ve learned new assays, with different analysers and I’m still getting to grips with the IT system, so the last few weeks have been a steep learning curve but never dull. Krishna Ram - Having now worked with Sysmex haemostasis analysers for many years, from the CA-Series to the CS-Series and now the CN-Series, do you think the advancement in technology and software on the CN-Series meets the current and future needs of haemostasis laboratories? Dr. Gardiner - Yes – the CN-Series certainly delivers a very wide assay range with high throughput and in a small package. Maintenance, data backups, QC and calibration procedures are much faster and more straightforward with the CN-Series, so there is very little downtime at the start of the day. The CN software and touch screen technology is also very user-friendly. Krishna Ram - With your experience working with the CN-6500, what key analyser features stood out most for you? Dr. Gardiner - The ability to perform routine testing and specialist assays simultaneously, without a significant drop in throughput. The CN-6500 incorporates two components; Coag Function, and Immuno Function testing that work independently of one another, to maintain high workflow from the analyser overall. Krishna Ram - In your open-access published ar ticle, “A p er formance evaluation of chemiluminescence enz yme immunoassays on the Sysmex CN-6500 haemostasis analyser” your study evaluated assays for: soluble thrombomodulin (TM), thrombin-antithrombin (TAT), tissue plasminogen activator/plasminogen activator inhibitor 1 complex (tPAIC) and plasmin α2 plasmin inhibitor complex (PIC).
Comparability of TM, TAT, PIC and tPAI-C in 230 clinical plasma samples between the CN-6500 and HISCL-5000 analysers.
Krishna Ram - Thank you for your time and sharing your experience of the CN-6500.
Do you see there being a clinical need or interest in these assays for haemostasis service providers in the NHS?
Dr. Gardiner - My pleasure, thank you.
For more information on the CN-Series, please visit: https://www.sysmex.co.uk/n/products/products-detail/cn-series-analysers.html Author: Krishna Ram, Product Marketing Manager, Haemostasis. 7
